Motixafortide acetate is under clinical development by BioLineRx and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Motixafortide acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Motixafortide acetate overview
Motixafortide is under development for the treatment of metastatic pancreatic adenocarcinoma, metastatic pancreatic ductal adenocarcinoma, adenocarcinoma of gastric or gastroesophageal junction, squamous cell carcinoma or adenocarcinoma of the esophagus. The drug candidate is administered through subcutaneous and intravenous route. BL-8040 is a short synthetic peptide which acts by targeting chemokine (C-X-C Motif) receptor 4 (CXCR4).
The drug candidate was also under development for hematological cancers including chronic myeloid leukemia, relapsed/refractory acute myeloid leukemia (AML) and squamous non-small cell lung cancer (first and third-line therapy), non-Hodgkin's lymphoma, neuroblastoma, melanoma, thrombocytopenia, aplastic anemia (AA), hypoplastic myelodysplastic syndrome, small cell lung cancer and acute respiratory distress syndrome (ARDS) secondary to COVID-19, acute myeloid leukemia and other respiratory viral infections.
BioLineRx overview
BioLineRx is a biopharmaceutical company. It is focused on developing therapies for oncology and rare diseases, primarily advancing its lead product, aphexda (motixafortide), a peptide approved for stem cell mobilization in multiple myeloma. Motixafortide targets the CXCR4 receptor, essential for hematopoietic stem cell retention and tumor progression. BioLineRx is exploring its potential for treating sickle cell disease and pancreatic cancer through collaborations with Washington University School of Medicine and Merck & Co., respectively. The company also offers BL-5010, a non-surgical solution for skin lesion removal, licensed to Perrigo for over-the-counter use. BioLineRx is headquartered in Modi’in, Israel.
For a complete picture of Motixafortide acetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
